Lexeo Therapeutics reaches FDA alignment on development plan for LX2006
PremiumThe FlyLexeo Therapeutics reaches FDA alignment on development plan for LX2006
2d ago
Lexeo Therapeutics reports Q3 EPS (89c), consensus (68c)
Premium
The Fly
Lexeo Therapeutics reports Q3 EPS (89c), consensus (68c)
2d ago
Lexeo Therapeutics sees cash runway into 2027
Premium
The Fly
Lexeo Therapeutics sees cash runway into 2027
2d ago
Lexeo Therapeutics participates in a conference call with JPMorgan
PremiumThe FlyLexeo Therapeutics participates in a conference call with JPMorgan
4M ago
Lexeo Therapeutics reports ‘positive’ results from LX2006 study
Premium
The Fly
Lexeo Therapeutics reports ‘positive’ results from LX2006 study
4M ago
Lexeo Therapeutics to report interim Phase 1/2 clinical data of LX2006
Premium
The Fly
Lexeo Therapeutics to report interim Phase 1/2 clinical data of LX2006
4M ago
Lexeo sees cash, equivalents sufficient to fund operations into 2027
PremiumThe FlyLexeo sees cash, equivalents sufficient to fund operations into 2027
6M ago
Lexeo Therapeutics reports Q1 EPS (77c), consensus (77c)
Premium
The Fly
Lexeo Therapeutics reports Q1 EPS (77c), consensus (77c)
6M ago
Bernard Davitian to Exit Board of Lexeo Therapeutics
Premium
Company Announcements
Bernard Davitian to Exit Board of Lexeo Therapeutics
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100